Nurix Therapeutics (NRIX) Earnings Date & Reports

Nurix Therapeutics reported collaboration revenue of $6.3 million for the fiscal first quarter ended February 28, 2026, down sharply from $18.5 million in the year-ago quarter. The decline stemmed from the conclusion of initial research terms for certain targets in the Sanofi partnership. This figure missed consensus expectations of approximately $14.25 million.

Research and development expenses climbed to $84.1 million from $69.7 million year-over-year, fueled by higher personnel costs, clinical trial activities, and manufacturing for the bexobrutideg program. General and administrative expenses increased to $14.6 million from $11.7 million, mainly due to personnel-related expenses.

Net loss expanded to $87.2 million, or ($0.79) per share, versus $56.4 million, or ($0.67) per share, last year. The EPS result fell short of analyst consensus of ($0.76). No specific guidance was updated, but the company emphasized pipeline progress.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener today to enhance your investment strategy.

Market Reaction and Investor Sentiment

Following the April 8, 2026, earnings release, NRIX shares showed mixed initial reaction, edging higher in pre-market trading by about 3% before moderating. The stock traded around $16.30 by April 14, reflecting focus on pipeline updates over the revenue miss and wider loss. Year-to-date, shares have declined amid broader biotech sector pressures, but analysts maintain a positive outlook with an average price target of $30.24. Sentiment hinges on clinical execution rather than near-term financials.

Forward Outlook and Key Factors to Monitor

Nurix's forward path centers on its lead candidate, bexobrutideg (NX-5948), with enrollment ongoing in the Phase 2 DAYBreak CLL-201 trial for relapsed/refractory CLL. This single-arm study supports potential accelerated approval, targeting patients progressed after covalent BTK inhibitor (cBTKi), BCL-2 inhibitor, and non-covalent BTK inhibitor therapies. Investors should track topline data expected at medical meetings in 2026.

By mid-2026, the company plans to start the global Phase 3 DAYBreak CLL-306 trial, comparing bexobrutideg to pirtobrutinib for full approval. Additional Phase 1b cohorts test higher doses in earlier CLL lines, with updates anticipated throughout the year.

Beyond oncology, a new tablet formulation advances toward a 2026 IND filing for immunology indications. Partnerships remain vital: Sanofi's STAT6 degrader NX-3911 nears IND-enabling studies, Gilead's IRAK4 degrader GS-6791 enters Phase 1, and Pfizer collaboration yields milestones. With $540.7 million in cash, Nurix funds operations without dilution risks soon.

Key monitors include trial enrollment rates, safety data, milestone payments, and macroeconomic biotech funding trends. No profitability timeline is set, emphasizing clinical catalysts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations